Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future
ABSTRACT Background Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinica...
Saved in:
Published in | Journal of gastroenterology and hepatology Vol. 40; no. 4; pp. 808 - 820 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Wiley Subscription Services, Inc
01.04.2025
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | ABSTRACT
Background
Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD).
Methods
A detailed literature search was performed.
Results
Albumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half‐life (17–19 h) due to neonatal Fc‐receptor‐mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high‐quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels.
Conclusions
Understanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision‐making. |
---|---|
AbstractList | ABSTRACT
Background
Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD).
Methods
A detailed literature search was performed.
Results
Albumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half‐life (17–19 h) due to neonatal Fc‐receptor‐mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high‐quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels.
Conclusions
Understanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision‐making. BackgroundCirculating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD).MethodsA detailed literature search was performed.ResultsAlbumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half‐life (17–19 h) due to neonatal Fc‐receptor‐mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high‐quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels.ConclusionsUnderstanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision‐making. Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD). A detailed literature search was performed. Albumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half-life (17-19 h) due to neonatal Fc-receptor-mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high-quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels. Understanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision-making. Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD).BACKGROUNDCirculating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of albumin, its place in nutritional assessment, current understanding of perturbed circulating concentrations, and role in clinical management, with special focus on patients with inflammatory bowel disease (IBD).A detailed literature search was performed.METHODSA detailed literature search was performed.Albumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half-life (17-19 h) due to neonatal Fc-receptor-mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high-quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels.RESULTSAlbumin is synthesized by hepatocytes and comprises 3% of total body protein. It has a prolonged intravascular half-life (17-19 h) due to neonatal Fc-receptor-mediated salvage and has a multitude of physiological functions. Albumin homeostasis is affected in disease states often resulting in reduced level, which is not a direct marker of malnutrition. In patients with IBD, morbid albumin concentrations provide prognostic information, identification of nonintestinal conditions, guidance to the required aggressiveness of therapy and biologic dosage, monitoring of disease activity, and potential need for therapeutic escalation. Barriers to utilization of morbid albumin levels include the lack of consensus regarding cutoff values and the deficiency of high-quality data in this domain due to the retrospective design of the majority of studies. Serum levels hold greatest clinical potential in prognostication in acute severe ulcerative colitis. The premorbid level in the individual may provide insight into dosing of biologics and potentially enhance interpretation of morbid levels.Understanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision-making.CONCLUSIONSUnderstanding the physiology and pathophysiology of albumin is fundamental to interpreting its circulating levels. The clinical value of its measurement in patients with IBD may be undervalued, as it assists in evaluation of disease severity, prognosis, and therapeutic decision-making. |
Author | Gibson, David J. Sparrow, Miles P. Ward, Mark G. Gibson, Peter R. Cameron, Karla Nguyen, Anke L. |
AuthorAffiliation | 1 Department of Gastroenterology, School of Translational Medicine Monash University and Alfred Health Melbourne Victoria Australia |
AuthorAffiliation_xml | – name: 1 Department of Gastroenterology, School of Translational Medicine Monash University and Alfred Health Melbourne Victoria Australia |
Author_xml | – sequence: 1 givenname: Karla orcidid: 0009-0009-0113-3941 surname: Cameron fullname: Cameron, Karla organization: Monash University and Alfred Health – sequence: 2 givenname: Anke L. surname: Nguyen fullname: Nguyen, Anke L. organization: Monash University and Alfred Health – sequence: 3 givenname: David J. surname: Gibson fullname: Gibson, David J. organization: Monash University and Alfred Health – sequence: 4 givenname: Mark G. surname: Ward fullname: Ward, Mark G. organization: Monash University and Alfred Health – sequence: 5 givenname: Miles P. surname: Sparrow fullname: Sparrow, Miles P. organization: Monash University and Alfred Health – sequence: 6 givenname: Peter R. orcidid: 0000-0001-9108-1712 surname: Gibson fullname: Gibson, Peter R. email: peter.gibson@monash.edu organization: Monash University and Alfred Health |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39894941$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kV9LHDEUxYNY6rrtQ79ACfSlgqPJJJOZ-CJb_26RCqLPITNzx82SSTSZcdlvb3SttIXmJbnkdw_ncHbRtvMOEPpCyQFN53B5vzigopLFFppQzklGSy620YRUtMgko3IH7ca4JIRwUhYf0Q6TleSS0wlqb-DJwArPwmAaC0d4ZuuxNw5r1-L5EPGNt4DTPHed1X2vBx_W-IdfgcWnJoKOaed2Afjatvt4SI9fsNp_3X4ZzsdhDPAJfei0jfD57Z6iu_Oz25PL7Or6Yn4yu8oaTniRdVBrWnDKBCt4rpnQkpG6YTqvGM8JYylOK7qupC0UUNEGGKFlUdacdVrzlk3R8Ub3Yax7aBtwQ9BWPQTT67BWXhv1948zC3XvnxSlUiRxkRS-vykE_zhCHFRvYgPWagd-jIpRkVdcCp4n9Ns_6NKPwaV8iaoESd5SlCn6-qeldy-_G0jA3gZogo8xQPeOUKJe2lWpXfXabmIPN-zKWFj_H1Q_Ly43G89qKqNk |
Cites_doi | 10.1093/ecco-jcc/jjaa268 10.1097/DCR.0000000000002831 10.1111/jgh.14962 10.1136/gut.38.1.99 10.1007/BF02236563 10.1097/MIB.0000000000001043 10.1038/s42003-020-0903-7 10.2147/IJGM.S102819 10.1046/j.1523-1755.1999.00298.x 10.1093/ecco-jcc/jjz083 10.1084/jem.20021829 10.1093/ibd/izaa309 10.1136/bmjgast-2021-000662 10.1016/0895-4356(92)90081-W 10.1002/jpen.1451 10.1097/MEG.0000000000000548 10.1136/gut.35.2.231 10.1002/jgh3.12506 10.1093/ecco-jcc/jjz195 10.1007/s12630-018-1181-4 10.1111/apt.13243 10.1371/journal.pone.0241558 10.1097/MD.0000000000025200 10.2215/CJN.09670620 10.1002/jgh3.13059 10.1016/S0039-6060(05)80251-X 10.18632/oncotarget.24172 10.2214/ajr.136.5.883 10.1016/j.cgh.2014.07.041 10.1111/j.1399-6576.1981.tb01622.x 10.3748/wjg.v23.i45.8008 10.1016/0002-9378(70)90364-9 10.1002/hep.1840120517 10.1136/bcr-2020-238802 10.1053/j.gastro.2015.04.016 10.1093/ecco-jcc/jjae094 10.1113/jphysiol.1896.sp000596 10.12659/MSM.897460 10.5414/CPP48297 10.1097/01.MIB.0000173271.18319.53 10.1172/JCI105885 10.1002/jgh3.12017 10.1097/MCG.0000000000000884 10.1093/ibd/izab285 10.1093/ecco-jcc/jjaa042 10.1016/j.ultrasmedbio.2020.12.001 10.1016/j.cgh.2018.06.031 10.1097/MD.0000000000024925 10.1111/j.1365-2036.2004.01945.x 10.1016/S0140-6736(18)30840-7 10.1016/B978-012552110-9/50006-4 10.1093/ecco-jcc/jjy028 10.1002/jcph.2384 10.1148/radiology.135.3.7384460 10.1007/s10620-016-4089-2 10.1111/j.1440-1746.2004.03486.x 10.1155/2020/3467419 10.1186/s12876-022-02113-3 10.1016/j.cgh.2014.07.055 10.1097/MIB.0000000000000212 10.1111/j.1440-1746.1996.tb01377.x 10.1093/ibd/izaa088 10.3109/00365521.2016.1144781 10.1097/00003643-200310000-00003 10.1186/s12876-022-02271-4 10.1111/apt.13934 10.1186/cc6812 10.1093/ibd/izx055 10.1159/000437077 |
ContentType | Journal Article |
Copyright | 2025 The Author(s). published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. 2025 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. 2025. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2025 The Author(s). published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. – notice: 2025 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. – notice: 2025. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 K9. 7X8 5PM |
DOI | 10.1111/jgh.16895 |
DatabaseName | Wiley Open Access Collection CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1440-1746 |
EndPage | 820 |
ExternalDocumentID | PMC11968156 39894941 10_1111_jgh_16895 JGH16895 |
Genre | reviewArticle Journal Article Review |
GrantInformation_xml | – fundername: Crohn's Colitis Australia funderid: Ferring Research Grant – fundername: CSL Behring – fundername: Monash University – fundername: Crohn's Colitis Australia grantid: Ferring Research Grant |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OB 1OC 24P 29K 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F D-I DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DTERQ DU5 EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO KMS LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOQ WOW WQJ WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAYXX AEYWJ AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 K9. 7X8 5PM |
ID | FETCH-LOGICAL-c4045-feba1541363542a36a930bc3a28342033815d6ff71de5e81ce301757b43faa4d3 |
IEDL.DBID | DR2 |
ISSN | 0815-9319 1440-1746 |
IngestDate | Thu Aug 21 18:37:38 EDT 2025 Fri Jul 11 03:01:38 EDT 2025 Wed Aug 13 09:01:21 EDT 2025 Mon Jul 21 06:01:12 EDT 2025 Tue Jul 01 05:17:19 EDT 2025 Fri Apr 04 09:53:20 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | protein turnover hypoalbuminaemia albumin Crohn's disease nutritional assessment ulcerative colitis diagnostic test therapeutic drug monitoring |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2025 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4045-feba1541363542a36a930bc3a28342033815d6ff71de5e81ce301757b43faa4d3 |
Notes | This work was supported by CSL Behring, Crohn's Colitis Australia (Ferring Research Grant), and Monash University. Funding ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 Funding: This work was supported by CSL Behring, Crohn's Colitis Australia (Ferring Research Grant), and Monash University. |
ORCID | 0009-0009-0113-3941 0000-0001-9108-1712 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjgh.16895 |
PMID | 39894941 |
PQID | 3186030141 |
PQPubID | 2045136 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11968156 proquest_miscellaneous_3162849642 proquest_journals_3186030141 pubmed_primary_39894941 crossref_primary_10_1111_jgh_16895 wiley_primary_10_1111_jgh_16895_JGH16895 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2025 |
PublicationDateYYYYMMDD | 2025-04-01 |
PublicationDate_xml | – month: 04 year: 2025 text: April 2025 |
PublicationDecade | 2020 |
PublicationPlace | Australia |
PublicationPlace_xml | – name: Australia – name: Richmond – name: Hoboken |
PublicationTitle | Journal of gastroenterology and hepatology |
PublicationTitleAlternate | J Gastroenterol Hepatol |
PublicationYear | 2025 |
Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
References | 2021; 27 2017; 1 1990; 12 2015; 149 2019; 13 2000; 43 2015; 33 2017; 45 2019; 17 2020; 15 2011; 11 2020; 14 2018; 41 2022; 22 1996; 38 2022; 28 2003; 197 1980; 135 2014; 20 2018; 9 2020; 3 2024; 8 2015; 42 1999; 55 1994; 35 2024; 64 2024; 67 1992; 45 1968; 47 2015; 13 2021; 47 2021; 8 2021; 5 2017; 23 1995; 117 1981; 25 2008; 12 1995 2016; 51 2020; 35 2021; 100 2018; 65 1970; 106 2024; 18 1996; 11 2018; 24 2021; 14 2021; 16 2010; 42 2021; 15 2018; 391 2010; 48 2020; 2020 2023 2004; 19 2019; 43 1981; 136 2017; 55 2018; 52 2016; 61 2018; 12 2016; 28 2003; 20 2005; 11 2016; 9 1896; 19 2016; 22 e_1_2_14_73_1 e_1_2_14_75_1 e_1_2_14_31_1 e_1_2_14_52_1 e_1_2_14_50_1 e_1_2_14_71_1 e_1_2_14_10_1 e_1_2_14_56_1 Fulks M. (e_1_2_14_8_1) 2010; 42 e_1_2_14_12_1 e_1_2_14_33_1 e_1_2_14_54_1 e_1_2_14_14_1 e_1_2_14_39_1 e_1_2_14_16_1 e_1_2_14_37_1 e_1_2_14_58_1 e_1_2_14_6_1 e_1_2_14_60_1 e_1_2_14_2_1 e_1_2_14_41_1 e_1_2_14_64_1 e_1_2_14_20_1 e_1_2_14_4_1 e_1_2_14_62_1 e_1_2_14_45_1 Mokhele N. (e_1_2_14_48_1) 2017; 55 e_1_2_14_68_1 e_1_2_14_24_1 e_1_2_14_43_1 e_1_2_14_66_1 e_1_2_14_22_1 e_1_2_14_28_1 e_1_2_14_49_1 e_1_2_14_26_1 e_1_2_14_47_1 e_1_2_14_19_1 Fukunaga S. (e_1_2_14_35_1) 2018; 41 e_1_2_14_72_1 e_1_2_14_74_1 e_1_2_14_30_1 e_1_2_14_53_1 e_1_2_14_51_1 e_1_2_14_70_1 e_1_2_14_11_1 e_1_2_14_34_1 e_1_2_14_57_1 e_1_2_14_13_1 e_1_2_14_32_1 e_1_2_14_55_1 Roberts I. (e_1_2_14_23_1) 2011; 11 e_1_2_14_15_1 e_1_2_14_38_1 e_1_2_14_76_1 e_1_2_14_17_1 e_1_2_14_36_1 e_1_2_14_59_1 e_1_2_14_29_1 e_1_2_14_5_1 e_1_2_14_7_1 e_1_2_14_9_1 e_1_2_14_42_1 e_1_2_14_63_1 e_1_2_14_3_1 e_1_2_14_40_1 e_1_2_14_61_1 e_1_2_14_46_1 e_1_2_14_67_1 e_1_2_14_21_1 e_1_2_14_44_1 e_1_2_14_27_1 e_1_2_14_25_1 e_1_2_14_69_1 Choy M. C. (e_1_2_14_65_1) 2024; 18 e_1_2_14_18_1 |
References_xml | – volume: 45 start-page: 213 issue: 3 year: 1992 end-page: 221 article-title: Serum Albumin in Older Persons: Relationship With Age and Health Status publication-title: Journal of Clinical Epidemiology – volume: 28 start-page: e10 issue: 3 year: 2016 end-page: e18 article-title: The Clinical Management of Abdominal Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: A Review of Current Guidelines and Recommendations publication-title: European Journal of Gastroenterology & Hepatology – volume: 135 start-page: 713 issue: 3 year: 1980 end-page: 716 article-title: Ultrasonographic Evidence of Gallbladder Wall Thickening in Association With Hypoalbuminemia publication-title: Radiology – volume: 67 start-page: 97 issue: 1 year: 2024 end-page: 106 article-title: Impact of Preoperative Factors in Patients With IBD on Postoperative Length of Stay: A National Surgical Quality Improvement Program‐Inflammatory Bowel Disease Collaborative Analysis publication-title: Diseases of the Colon and Rectum – volume: 197 start-page: 315 issue: 3 year: 2003 end-page: 322 article-title: The Major Histocompatibility Complex‐Related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan publication-title: Journal of Experimental Medicine – volume: 65 start-page: 1218 issue: 11 year: 2018 end-page: 1227 article-title: Association Between Albumin Administration and Survival in Cardiac Surgery: A Retrospective Cohort Study publication-title: Canadian Journal of Anaesthesia – volume: 43 start-page: 181 issue: 2 year: 2019 end-page: 193 article-title: Hypoalbuminemia: Pathogenesis and Clinical Significance publication-title: Journal of Parenteral and Enteral Nutrition – volume: 38 start-page: 99 year: 1996 end-page: 103 article-title: Microalbuminuria Correlates With Intestinal Histopathological Grading in Patients With Inflammatory Bowel Disease publication-title: Gut – volume: 47 start-page: 1958 issue: 9 year: 1968 end-page: 1972 article-title: Albumin Metabolism: Effect of the Nutritional State and the Dietary Protein Intake publication-title: Journal of Clinical Investigation – volume: 14 start-page: 1231 year: 2020 end-page: 1240 article-title: Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti‐Tumour Necrosis Factor Therapy publication-title: Journal of Crohn's & Colitis – volume: 23 start-page: 8008 issue: 45 year: 2017 end-page: 8016 article-title: Albumin as a Prognostic Marker for Ulcerative Colitis publication-title: World Journal of Gastroenterology – volume: 64 start-page: 399 issue: 4 year: 2024 end-page: 409 article-title: Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis publication-title: Journal of Clinical Pharmacology – volume: 5 start-page: 377 issue: 3 year: 2021 end-page: 381 article-title: Low Serum Albumin at Admission Is a Predictor of Early Colectomy in Patients With Moderate to Severe Ulcerative Colitis publication-title: JGH Open – volume: 43 start-page: 1141 issue: 8 year: 2000 end-page: 1145 article-title: Risk Factors for Intra‐Abdominal Sepsis After Surgery in Crohn's Disease publication-title: Diseases of the Colon and Rectum – volume: 61 start-page: 2051 issue: 7 year: 2016 end-page: 2059 article-title: Long‐Term Follow‐Up of Patients Treated With Infliximab for Ulcerative Colitis: Predictive Factors of Response‐An Observational Study publication-title: Digestive Diseases and Sciences – volume: 25 start-page: 125 year: 1981 end-page: 132 article-title: Albumin Treatment Following Major Surgery. Effects on Plasma Oncotic Pressure, Renal Function and Peripheral Oedema publication-title: Acta Anaesthesiologica Scandinavica – volume: 47 start-page: 1108 issue: 4 year: 2021 end-page: 1114 article-title: Early Assessment With Gastrointestinal Ultrasound in Patients Hospitalised for a Flare of Ulcerative Colitis and Predicting the Need for Salvage Therapy: A Pilot Study publication-title: Ultrasound in Medicine & Biology – volume: 9 start-page: 13934 issue: 17 year: 2018 end-page: 13947 article-title: Clinicopathologic and Prognostic Significance of C‐Reactive Protein/Albumin Ratio in Patients With Solid Tumours: An Updated Systematic Review and meta Analysis publication-title: Oncotarget – volume: 3 start-page: 181 issue: 1 year: 2020 article-title: An Intact C‐Terminal end of Albumin Is Required for Its Long Half‐Life in Humans publication-title: Communications Biology – volume: 1 start-page: 98 issue: 3 year: 2017 end-page: 104 article-title: Blood Biomarkers Reflect Integration of Severity and Extent of Endoscopic Inflammation in Ulcerative Colitis publication-title: JGH Open – volume: 18 issue: January 2024 year: 2024 article-title: P872 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis—A Randomised Controlled Trial publication-title: Journal of Crohn's and Colitis – volume: 33 start-page: 61 issue: Suppl 1 year: 2015 end-page: 69 article-title: The Pharmacokinetics of Biologics: A Primer publication-title: Digestive Diseases – volume: 18 start-page: 1870 year: 2024 end-page: 1878 article-title: Intravenous Albumin Infusion Does Not Augment the Response Rate to a Combination of Exclusive Enteral Nutrition and Intravenous Steroids in Acute Severe Ulcerative Colitis: A Randomized Controlled Trial publication-title: Journal of Crohn's & Colitis – volume: 14 start-page: 694 issue: 5 year: 2020 end-page: 709 article-title: Predictors of Primary Response to Biologic Treatment [Anti‐TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice publication-title: Journal of Crohn's & Colitis – volume: 41 start-page: 107 issue: 1 year: 2018 end-page: 118 article-title: Detection of Calprotectin in Inflammatory Bowel Disease: Fecal and Serum Levels and Immunohistochemical Localization publication-title: International Journal of Molecular Medicine – volume: 15 start-page: 1142 issue: 7 year: 2021 end-page: 1151 article-title: Hypoalbuminaemia, Not Biologic Exposure, Is Associated With Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection publication-title: Journal of Crohn's & Colitis – volume: 22 start-page: 39 issue: 1 year: 2022 article-title: Effect of Disease Duration on the Association Between C‐Reactive Protein‐Albumin Ratio and Endoscopic Activity in Ulcerative Colitis publication-title: BMC Gastroenterology – volume: 391 start-page: 2417 issue: 10138 year: 2018 end-page: 2429 article-title: Long‐Term Albumin Administration in Decompensated Cirrhosis (ANSWER): An Open‐Label Randomised Trial publication-title: Lancet – volume: 100 issue: 10 year: 2021 article-title: C‐Reactive Protein/Abumin Ratio Is a Useful Biomarker for Predicting the Mucosal Healing in the Crohn Disease: A Retrospective Study publication-title: Medicine (Baltimore) – volume: 52 start-page: e48 issue: 6 year: 2018 end-page: e52 article-title: CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis publication-title: Journal of Clinical Gastroenterology – volume: 13 start-page: 531 year: 2015 end-page: 538 article-title: A Panel to Predict Long‐Term Outcome of Infliximab Therapy for Pateints With Ulcerative Colitis publication-title: Clinical Gastroenterology and Hepatology – volume: 9 start-page: 229 year: 2016 end-page: 255 article-title: Human Serum Albumin Homeostasis: A New Look at the Roles of Synthesis, Catabolism, Renal and Gastrointestinal Excretion, and the Clinical Value of Serum Albumin Measurements publication-title: International Journal of General Medicine – volume: 48 start-page: 297 issue: 5 year: 2010 end-page: 308 article-title: Serum Albumin Concentration: A Predictive Factor of Infliximab Pharmacokinetics and Clinical Response in Patients With Ulcerative Colitis publication-title: International Journal of Clinical Pharmacology and Therapeutics – volume: 13 start-page: 1433 issue: 11 year: 2019 end-page: 1438 article-title: Hypoalbuminaemia and Postoperative Outcomes in Inflammatory Bowel Disease: The NSQIP Surgical Cohort publication-title: Journal of Crohn's & Colitis – volume: 149 start-page: 350 issue: 2 year: 2015 end-page: 355 article-title: Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis publication-title: Gastroenterology – volume: 28 start-page: 1375 year: 2022 end-page: 1385 article-title: Dashboard‐Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity publication-title: Inflammatory Bowel Diseases – volume: 12 start-page: 1179 issue: 5 year: 1990 end-page: 1186 article-title: Acute‐Phase Response of Human Hepatocytes: Regulation of Acute‐Phase Protein Synthesis by Interleukin‐6 publication-title: Hepatology – volume: 11 start-page: 311 year: 1996 end-page: 318 article-title: Measurement of Faecal Alpha 1‐Antitrypsin: Methodologies and Clinical Application publication-title: Journal of Gastroenterology and Hepatology – volume: 117 start-page: 520 issue: 5 year: 1995 end-page: 530 article-title: Hepatic Metabolic Response to Injury and sepsis publication-title: Surgery – volume: 20 start-page: 771 issue: 10 year: 2003 end-page: 793 article-title: Albumin Administration—What Is the Evidence of Clinical Benefit? A Systematic Review of Randomized Controlled Trials publication-title: European Journal of Anaesthesiology – volume: 27 start-page: 451 issue: 4 year: 2021 end-page: 457 article-title: The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission That Predicts Outcome in Patients With Acute Ulcerative Colitis publication-title: Inflammatory Bowel Diseases – volume: 19 start-page: 1247 year: 2004 end-page: 1252 article-title: Severe Ulcerative Colitis: Prospective Study of Parameters Determining Outcome publication-title: Journal of Gastroenterology and Hepatology – volume: 23 start-page: 650 issue: 4 year: 2017 end-page: 660 article-title: A Real‐Life Population Pharmacokinetic Study Reveals Factors Associated With Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease publication-title: Inflammatory Bowel Diseases – volume: 51 start-page: 934 issue: 8 year: 2016 end-page: 941 article-title: Prediction of Clinical and Endoscopic Responses to Anti‐Tumor Necrosis Factor‐Alpha Antibodies in Ulcerative Colitis publication-title: Scandinavian Journal of Gastroenterology – volume: 136 start-page: 883 year: 1981 end-page: 886 article-title: Radiologic Features of the Jejunum in Hypoalbuminemia publication-title: American Journal of Roentgenology – volume: 27 start-page: 1452 issue: 9 year: 2021 end-page: 1461 article-title: Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti‐TNF Treatment publication-title: Inflammatory Bowel Diseases – volume: 13 start-page: 330 issue: 2 year: 2015 end-page: 335 article-title: An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis publication-title: Clinical Gastroenterology and Hepatology – volume: 14 start-page: 1 year: 2021 end-page: 5 article-title: Protein‐Losing Enteropathy as Precursor of Inflammtory Bowel Disease: A Review of the Literature publication-title: BMJ Case Reports – volume: 100 issue: 14 year: 2021 article-title: Accuracy of the Highly Sensitive C‐Reactive Protein/Albumin Ratio to Determine Disease Activity in Inflammatory Bowel Disease publication-title: Medicine (Baltimore) – volume: 55 start-page: 629 issue: 2 year: 1999 end-page: 634 article-title: Coadministration of Albumin and Furosemide in Patients With the Nephrotic Syndrome publication-title: Kidney International – volume: 20 start-page: 2247 issue: 12 year: 2014 end-page: 2259 article-title: Patient Factors That Increase Infliximab Clearance and Shorten Half‐Life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study publication-title: Inflammatory Bowel Diseases – volume: 12 start-page: 662 issue: 6 year: 2018 end-page: 669 article-title: Accelerated Clearance of Infliximab Is Associated With Treatment Failure in Patients With Corticosteroid‐Refractory Acute Ulcerative Colitis publication-title: Journal of Crohn's & Colitis – volume: 16 start-page: 820 issue: 5 year: 2021 end-page: 828 article-title: Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration During Kidney Replacement Therapy publication-title: Clinical Journal of the American Society of Nephrology – volume: 35 start-page: 1163 issue: 7 year: 2020 end-page: 1170 article-title: Clinical Relevance of Innovative Immunoassays for Serum Ustekinumab and Anti‐Ustekinumab Antibody Levels in Crohn's Disease publication-title: Journal of Gastroenterology and Hepatology – volume: 22 start-page: 195 issue: 1 year: 2022 article-title: Ustekinumab Trough Levels Predicting Laboratory and Endoscopic Remission in Patients With Crohn's Disease publication-title: BMC Gastroenterology – volume: 15 issue: 11 year: 2020 article-title: Commonly Used Clinical Chemistry Tests as Mortality Predictors: Results From Two Large Cohort Studies publication-title: PLoS ONE – volume: 19 start-page: 1079 issue: 10 year: 2004 end-page: 1087 article-title: Predicting the Outcome of Severe Ulcerative Colitis: Development of a Novel Risk Score to aid Early Selection of Patients for Second‐Line Medical Therapy or Surgery publication-title: Alimentary Pharmacology & Therapeutics – volume: 24 start-page: 839 issue: 4 year: 2018 end-page: 848 article-title: Fecal Calprotectin During Pregnancy in Women With Moderate‐Severe Inflammatory Bowel Disease publication-title: Inflammatory Bowel Diseases – volume: 106 start-page: 388 issue: 3 year: 1970 end-page: 399 article-title: Serum Protein Concentrations in Pregnancy. 1. Concentrations in Maternal Serum publication-title: American Journal of Obstetrics and Gynecology – volume: 8 issue: 4 year: 2024 article-title: Clinical Utility of C‐Reactive Protein‐To‐Albumin Ratio in the Management of Patients With Inflammatory Bowel Disease publication-title: JGH Open – volume: 12 start-page: R34 issue: 2 year: 2008 article-title: Small‐Volume Resuscitation With Hyperoncotic Albumin: A Systematic Review of Randomized Clinical Trials publication-title: Critical Care – volume: 22 start-page: 4393 year: 2016 end-page: 4400 article-title: Serum Albumin and C‐Reactive Protein/Albumin Ratio Are Useful Biomarkers of Crohn's Disease Activity publication-title: Medical Science Monitor – volume: 19 start-page: 312 issue: 4 year: 1896 end-page: 326 article-title: On the Absorption of Fluids From the Connective Tissue Spaces publication-title: Journal of Physiology – year: 2023 – volume: 8 issue: 1 year: 2021 article-title: Effect of Disease Duration on the Association Between Serum Albumin and Mucosal Healing in Patients With Ulcerative Colitis publication-title: BMJ Open Gastroenterology – year: 1995 – volume: 42 start-page: 11 year: 2010 end-page: 17 article-title: Albumin and All‐Cause Mortality Risk in Insurance Applicants publication-title: Journal of Insurance Medicine – volume: 55 start-page: 20 issue: 3 year: 2017 end-page: 26 article-title: Predictors of Emergency Colectomy in Patients Admitted With Acute Severe Ulcerative Colitis publication-title: South African Journal of Surgery – volume: 45 start-page: 660 issue: 5 year: 2017 end-page: 669 article-title: Exclusive Enteral Nutrition Provides an Effective Bridge to Safer Interval Elective Surgery for Adults With Crohn's Disease publication-title: Alimentary Pharmacology & Therapeutics – volume: 11 year: 2011 article-title: Human Albumin Solution for Resuscitation and Volume Expansion in Critically Ill Patients publication-title: Cochrane Database of Systematic Reviews – volume: 2020 year: 2020 article-title: The Relationship Between C‐Reactive Protein/Albumin Ratio and Disease Activity in Patients With Inflammatory Bowel Disease publication-title: Gastroenterology Research and Practice – volume: 11 start-page: 707 issue: 8 year: 2005 end-page: 712 article-title: Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease publication-title: Inflammatory Bowel Diseases – volume: 42 start-page: 188 issue: 2 year: 2015 end-page: 202 article-title: Population Pharmacokinetics‐Pharmacodynamics of Vedolizumab in Patients With Ulcerative Colitis and Crohn's Disease publication-title: Alimentary Pharmacology & Therapeutics – volume: 35 start-page: 231 year: 1994 end-page: 235 article-title: Correlations Between Clinical Activity, Endoscopic Severity, and Biological Parameters in Colonic or Ileocolonic Crohn's Disease. A Prospective Multicentre Study of 121 Cases publication-title: Gut – volume: 17 start-page: 502 issue: 3 year: 2019 end-page: 509 article-title: Effect of Accelerated Infliximab Induction on Short‐ and Long‐Term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta‐Analysis publication-title: Clinical Gastroenterology and Hepatology – ident: e_1_2_14_51_1 doi: 10.1093/ecco-jcc/jjaa268 – ident: e_1_2_14_49_1 doi: 10.1097/DCR.0000000000002831 – ident: e_1_2_14_71_1 doi: 10.1111/jgh.14962 – ident: e_1_2_14_28_1 doi: 10.1136/gut.38.1.99 – ident: e_1_2_14_52_1 doi: 10.1007/BF02236563 – ident: e_1_2_14_58_1 doi: 10.1097/MIB.0000000000001043 – ident: e_1_2_14_22_1 doi: 10.1038/s42003-020-0903-7 – ident: e_1_2_14_2_1 doi: 10.2147/IJGM.S102819 – ident: e_1_2_14_18_1 doi: 10.1046/j.1523-1755.1999.00298.x – ident: e_1_2_14_50_1 doi: 10.1093/ecco-jcc/jjz083 – ident: e_1_2_14_4_1 doi: 10.1084/jem.20021829 – ident: e_1_2_14_64_1 doi: 10.1093/ibd/izaa309 – ident: e_1_2_14_39_1 doi: 10.1136/bmjgast-2021-000662 – ident: e_1_2_14_5_1 doi: 10.1016/0895-4356(92)90081-W – ident: e_1_2_14_9_1 doi: 10.1002/jpen.1451 – ident: e_1_2_14_16_1 doi: 10.1097/MEG.0000000000000548 – ident: e_1_2_14_31_1 doi: 10.1136/gut.35.2.231 – ident: e_1_2_14_42_1 doi: 10.1002/jgh3.12506 – ident: e_1_2_14_61_1 doi: 10.1093/ecco-jcc/jjz195 – volume: 18 issue: 2024 year: 2024 ident: e_1_2_14_65_1 article-title: P872 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis—A Randomised Controlled Trial publication-title: Journal of Crohn's and Colitis – ident: e_1_2_14_20_1 doi: 10.1007/s12630-018-1181-4 – ident: e_1_2_14_69_1 doi: 10.1111/apt.13243 – ident: e_1_2_14_7_1 doi: 10.1371/journal.pone.0241558 – ident: e_1_2_14_34_1 doi: 10.1097/MD.0000000000025200 – ident: e_1_2_14_19_1 doi: 10.2215/CJN.09670620 – ident: e_1_2_14_56_1 doi: 10.1002/jgh3.13059 – ident: e_1_2_14_14_1 doi: 10.1016/S0039-6060(05)80251-X – ident: e_1_2_14_54_1 doi: 10.18632/oncotarget.24172 – ident: e_1_2_14_13_1 doi: 10.2214/ajr.136.5.883 – ident: e_1_2_14_46_1 doi: 10.1016/j.cgh.2014.07.041 – ident: e_1_2_14_24_1 doi: 10.1111/j.1399-6576.1981.tb01622.x – ident: e_1_2_14_40_1 doi: 10.3748/wjg.v23.i45.8008 – ident: e_1_2_14_6_1 doi: 10.1016/0002-9378(70)90364-9 – ident: e_1_2_14_15_1 doi: 10.1002/hep.1840120517 – ident: e_1_2_14_27_1 doi: 10.1136/bcr-2020-238802 – volume: 55 start-page: 20 issue: 3 year: 2017 ident: e_1_2_14_48_1 article-title: Predictors of Emergency Colectomy in Patients Admitted With Acute Severe Ulcerative Colitis publication-title: South African Journal of Surgery – ident: e_1_2_14_66_1 doi: 10.1053/j.gastro.2015.04.016 – ident: e_1_2_14_75_1 doi: 10.1093/ecco-jcc/jjae094 – ident: e_1_2_14_11_1 doi: 10.1113/jphysiol.1896.sp000596 – ident: e_1_2_14_30_1 doi: 10.12659/MSM.897460 – ident: e_1_2_14_60_1 doi: 10.5414/CPP48297 – volume: 11 year: 2011 ident: e_1_2_14_23_1 article-title: Human Albumin Solution for Resuscitation and Volume Expansion in Critically Ill Patients publication-title: Cochrane Database of Systematic Reviews – ident: e_1_2_14_38_1 doi: 10.1097/01.MIB.0000173271.18319.53 – ident: e_1_2_14_10_1 doi: 10.1172/JCI105885 – ident: e_1_2_14_37_1 doi: 10.1002/jgh3.12017 – ident: e_1_2_14_44_1 doi: 10.1097/MCG.0000000000000884 – ident: e_1_2_14_72_1 doi: 10.1093/ibd/izab285 – ident: e_1_2_14_32_1 doi: 10.1093/ecco-jcc/jjaa042 – ident: e_1_2_14_57_1 doi: 10.1016/j.ultrasmedbio.2020.12.001 – ident: e_1_2_14_74_1 doi: 10.1016/j.cgh.2018.06.031 – ident: e_1_2_14_33_1 doi: 10.1097/MD.0000000000024925 – ident: e_1_2_14_76_1 – ident: e_1_2_14_47_1 doi: 10.1111/j.1365-2036.2004.01945.x – ident: e_1_2_14_17_1 doi: 10.1016/S0140-6736(18)30840-7 – ident: e_1_2_14_3_1 doi: 10.1016/B978-012552110-9/50006-4 – ident: e_1_2_14_68_1 doi: 10.1093/ecco-jcc/jjy028 – ident: e_1_2_14_73_1 doi: 10.1002/jcph.2384 – ident: e_1_2_14_12_1 doi: 10.1148/radiology.135.3.7384460 – ident: e_1_2_14_63_1 doi: 10.1007/s10620-016-4089-2 – ident: e_1_2_14_43_1 doi: 10.1111/j.1440-1746.2004.03486.x – ident: e_1_2_14_36_1 doi: 10.1155/2020/3467419 – ident: e_1_2_14_55_1 doi: 10.1186/s12876-022-02113-3 – ident: e_1_2_14_41_1 doi: 10.1016/j.cgh.2014.07.055 – ident: e_1_2_14_59_1 doi: 10.1097/MIB.0000000000000212 – ident: e_1_2_14_26_1 doi: 10.1111/j.1440-1746.1996.tb01377.x – ident: e_1_2_14_45_1 doi: 10.1093/ibd/izaa088 – ident: e_1_2_14_62_1 doi: 10.3109/00365521.2016.1144781 – ident: e_1_2_14_21_1 doi: 10.1097/00003643-200310000-00003 – ident: e_1_2_14_70_1 doi: 10.1186/s12876-022-02271-4 – ident: e_1_2_14_53_1 doi: 10.1111/apt.13934 – volume: 41 start-page: 107 issue: 1 year: 2018 ident: e_1_2_14_35_1 article-title: Detection of Calprotectin in Inflammatory Bowel Disease: Fecal and Serum Levels and Immunohistochemical Localization publication-title: International Journal of Molecular Medicine – volume: 42 start-page: 11 year: 2010 ident: e_1_2_14_8_1 article-title: Albumin and All‐Cause Mortality Risk in Insurance Applicants publication-title: Journal of Insurance Medicine – ident: e_1_2_14_25_1 doi: 10.1186/cc6812 – ident: e_1_2_14_29_1 doi: 10.1093/ibd/izx055 – ident: e_1_2_14_67_1 doi: 10.1159/000437077 |
SSID | ssj0004075 |
Score | 2.4517674 |
SecondaryResourceType | review_article |
Snippet | ABSTRACT
Background
Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and... Circulating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles of... BackgroundCirculating albumin concentrations are frequently measured in clinical practice. This review explores biochemical properties and physiological roles... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 808 |
SubjectTerms | Albumin Biomarkers - blood Crohn's disease Decision making diagnostic test Fc receptors Hepatocytes Homeostasis Humans hypoalbuminaemia Inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - blood Inflammatory Bowel Diseases - diagnosis Inflammatory Bowel Diseases - physiopathology Inflammatory Bowel Diseases - therapy Intestine Malnutrition Neonates Nutrition Assessment nutritional assessment Pathophysiology Physiology Prognosis protein turnover Review Serum Albumin - metabolism Serum Albumin - physiology Serum levels therapeutic drug monitoring Ulcerative colitis |
Title | Review Article: Albumin and Its Role in Inflammatory Bowel Disease: The Old, the New, and the Future |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjgh.16895 https://www.ncbi.nlm.nih.gov/pubmed/39894941 https://www.proquest.com/docview/3186030141 https://www.proquest.com/docview/3162849642 https://pubmed.ncbi.nlm.nih.gov/PMC11968156 |
Volume | 40 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFD7qeEC8sMEGC4PKm_awB1I19aUxe9oGXVupG0Ig8YAU2bFD0boUra0m7dfv2LmspUJCe0sUW76ciz_7HH8BeN9RlDKXPZWlUodMsyhUSmYhs1pag4g-9vTFo2-if8WG1_y6AR-ruzAFP0R94OYsw_trZ-BKz5aN_HbcikQs3QVzl6vlANHFP-ooVpDsYls8lKhnJauQz-Kpaq6uRWsAcz1Pchm_-gWo9xxuqq4XeSc_Wou5bqV_HrA6_ufYXsB2CUzJp0KTdqBh813YHJWh95dgiihCVeCE-MP9u5yo3JDBfEYuphNL8H2QZ6hlP330nnye_rYTclpEgU4IKiX5PjHHBGEnQf967Gu7l57nNnkFV72zyy_9sPxFQ5gyBINhZrVCEIbzTzlDuQslaVunVCFqYZ027n8jbkSWdSNjuY2j1KJD6fKuZjRTihm6Bxv5NLevgfDUCqlUKhBTMoGjpyKNOaeZoVgtMgG8q4SV3BdMHEm9g7kdJ36-AjisxJiUxjhL0G0Jv3WMAnhbf0YzcrERldvpwpURuFBL3I0FsF9IvW6FOpJ66WrHK_pQF3AU3atf8ruxp-qO0ME5Pp4APnh5P97zZPi17x8Onl70DWx13O-IfSLRIWzMfy3sEWKkuW7Csw47b3qT-AscYgwi |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFD5iIG172diAEW7z0B54IBWuL40RL9y6FihICCReUOTEDkV06TRaIfHrd-xcRoeQ0N4SxZadnIu_43PyGeB7UzPGXfVUlqok5AmnodYqC7lNlDWI6CNPX9w7lZ1LfnQlrqZgp_oXpuCHqDfcnGV4f-0M3G1IP7Xym36DykiJNzDjTvT2AdX5X_IoXtDs4mgiVKhpJa-Qr-Opuk6uRs8g5vNKyacI1i9B7Y9wXU2-qDy5a4xHSSN9_IfX8X_fbhY-lNiU7BbK9AmmbP4Z3vbK7PscmCKRUDXYJn5__zYnOjekO7on58OBJXjfzTNUtJ8-gU_2hg92QA6KRNA2Qb0kZwOzSRB5EnSxm763u2l7epN5uGwfXux3wvKUhjDliAfDzCYacRhlCF04il5qxbaSlGkELry5hSEwFUZmWYsaK2xEU4s-pSVaCWeZ1tywBZjOh7ldBCJSK5XWKQpTcYlvz2QaCcEyw7AbNQGsV9KKfxVkHHEdxNz0Y_-9Alip5BiX9ngfo-eSPnqkAXyrH6MlufSIzu1w7NpIXKsVBmQBfCnEXo_CHE-9cr2jCYWoGziW7skn-W3fs3VT9HGOkieADS_wl2ceH_3o-Iul1zf9Cu86F72T-KR7erwM75vudGJfV7QC06PfY7uKkGmUrHnL-AN-oQ9m |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bTxQxFD5BTIgvCF5gELAaH3xgNtvtZafwhK7rLgoaIgkPJJPOtGUJyyyR3Zjw6zntXGQlJsa3aaZN2zmXfu058xXgXUczxn32lMtVFvOM01hr5WJuM2UNIvok0BcfHsnBCT84FacLsFf_C1PyQzQHbt4ygr_2Bn5t3H0jPx-1qEyUeASPuWwnXqV7x7-5o3jJsoudiViholW0QiGNp246vxg9QJgPEyXvA9iwAvWfwlk99jLx5LI1m2at_PYPWsf_nNwKLFfIlOyXqrQKC7Z4BkuHVez9OZgyjFBX2CXhdP-iILowZDi9IceTsSVYHhYO1ewqhO_Jh8kvOya9Mgy0S1Arybex2SGIOwk62J3Q2hf6gdzkBZz0P_34OIirOxrinCMajJ3NNKIwyhC4cBS81Iq1s5xphC2808YNMBVGOtelxgqb0NyiR-mKbsaZ05ob9hIWi0lh14GI3EqldS4RVHKJs2cyT4RgzjBsRk0Eb2thpdclFUfabGHOR2n4XhFs1mJMK2u8SdFvybB3pBG8aV6jHfngiC7sZObrSFypFW7HIlgrpd70wjxLvfKtkzl9aCp4ju75N8XFKHB1U_RwnpAngvdB3n8feXrweRAeNv696mtY-t7rp1-HR19ewZOOv5o4JBVtwuL058xuIV6aZtvBLu4AYqoOHg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Review+Article%3A+Albumin+and+Its+Role+in+Inflammatory+Bowel+Disease%3A+The+Old%2C+the+New%2C+and+the+Future&rft.jtitle=Journal+of+gastroenterology+and+hepatology&rft.au=Cameron%2C+Karla&rft.au=Nguyen%2C+Anke+L&rft.au=Gibson%2C+David+J&rft.au=Ward%2C+Mark+G&rft.date=2025-04-01&rft.eissn=1440-1746&rft.volume=40&rft.issue=4&rft.spage=808&rft_id=info:doi/10.1111%2Fjgh.16895&rft_id=info%3Apmid%2F39894941&rft.externalDocID=39894941 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0815-9319&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0815-9319&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0815-9319&client=summon |